Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Liquid Biopsies in Multiple Myeloma with Dr. Irene Ghobrial, MD, Dana Farber Cancer Institute

Posted on: Sep 27, 2017

Play Episode

Also available on

Spotify

Apple Podcasts

Youtube

Description

Irene Ghobrial, MD Dana Farber Cancer Institute Interview Date: September 27, 2017

Myeloma patients hate the bone marrow biopsy, which can determine the level of tumor burden as well as the genetics of myeloma. These biopsies are a literal pain in the butt for patients who see them as a necessity to gain information about how their disease is trending before and after treatment. Dr. Ghobrial shares the exciting news of the in-progress development of liquid biopsies (or biopsies taken from blood samples) that could track the DNA that is left when cancer cells die, but are still circulating in the blood. This great development would ease the burden on myeloma patients and would add incredible value to track the disease from early precursor stages through advanced disease with all of its iterative genetic changes. It would be particularly helpful for patients who have no M-spike (or are non-secretory). Learn more about how this new technology could dramatically improve patient's lives. Dr. Irene Ghobrial on Myeloma Crowd Radio

Thanks to our episode sponsor

Overview

Irene Ghobrial, MD Dana Farber Cancer Institute Interview Date: September 27, 2017

Thanks to our episode sponsor

On this episode

Irene Ghobrial, MD

Irene Ghobrial, MD, is a Professor at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School and an associate member of the Broad Institute. She is Director of the Michele & Stephen Kirsch Laboratory and co-director of the Center for Prevention of Progression (CPOP) at DFCI. Additionally, she is the co-leader of the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of community oncology sites coordinated by DFCI. Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma and Waldenström Macroglobulinemia. She specifically focuses on the role of malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored or co-authored more than 250 publications and book chapters. She has received multiple awards including membership in the American Society of Clinical Investigation, the Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and the Mentor of the Year Award at DFCI in 2014. Dr. Ghobrial completed her hematology/oncology subspecialty training at the Mayo Clinic College of Medicine in Rochester, MN and internal medicine training at Wayne State University in Detroit, MI. She earned her medical degree from the Cairo School of Medicine in Egypt.

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Transcript

Liquid Biopsies in Multiple Myeloma with Dr. Irene Ghobrial, MD, Dana Farber Cancer Institute

Related Content